header logo image


Page 43«..1020..41424344

Archive for September, 2020

CooperVision Announces Sarah Michelle Gellar as Spokesperson to Increase Awareness of Myopia Management and the Brilliant Futures Program with MiSight…

Wednesday, September 2nd, 2020

"CooperVision received FDA-approval of the MiSight 1 day contact lens on Nov. 15, 2019, making the United States our 18th market worldwide. This reinforced CooperVision as a leader in the myopia management category," said Daniel G. McBride, President of CooperVision. "In this particular moment in time, with so many children learning virtually and spending less time outdoors, the topic of myopia management is more relevant than ever before. As category creators and leaders in the myopia management sector, we believe it is our responsibility and privilege, alongside the optometric community, to educate parents and offer them tools to help their children who may be struggling with myopia. Our decision to make this sizable investment in educating parents is consistent with our view that addressing myopia early is vitally important."

This new, multichannel direct-to-consumer advertising campaign featuring Gellar will highlight the importance of annual comprehensive eye exams in monitoring the progression of myopia in children. The campaign will include national and regional broadcast segments, content across digital and social media, and influencers who will be sharing their personal experiences with myopia. In addition, CooperVision will be collaborating with the National Association of School Nurses(NASN) to engage in meaningful unbranded conversations about myopia with the organization's members. While the NASN does not endorse products, school nurses are often the first to observe the signs of myopia in affected children and are therefore important myopia management advocates.

"My husband and I are both nearsighted and our myopia has continued to worsen over time," said Gellar. "We want our kids to have a chance for better vision and lower their risk for future eye health issues. While regular eyeglasses or contacts help children see a whiteboard or tennis ball today, MiSight 1 day lenses offer children the benefits of clear vision while slowing myopia progression during their growing years*. That is why I am thrilled to be partnering with CooperVision on this campaign."

"CooperVision has always been committed to eye health innovation," said Jerry Warner,Executive Vice President, Americas and Global Commercial Functions of CooperVision. "The goal of this campaign is to help build awareness of the short and long term effects of myopia. More than just vision correction, CooperVision's myopia management program can help build a brilliant future for our children."

To learn more, visit https://coopervision.com/practitioner/myopia-management

* Indications for use: MiSight 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

Compared to a single vision 1 day lens over a 3 year period.

References:1Chamberlain P, et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019; 96(8): 556-567.2Holden BA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-42.3Cooper Y. (2019, May 1). With Childhood Myopia Rates on the Rise, the American Optometric Association Highlights the Importance of Early Intervention through Annual Eye Exams. Retrieved from https://www.aoa.org/newsroom/myopia-rates-on-the-rise-syvm.4CooperVision data on file 2019. Myopia Awareness, The Harris Poll online survey 6/27/19 to 7/18/19 of n=313 ECPs (who see at least 1/month myopic child, age 8-15) in U.S. Slightly or significantly increased.5CooperVision data on file 2019. Myopia Awareness, The Harris Poll online survey 6/27/19 to 7/18/19 of n=313 ECPs (who see at least 1/month myopic child, age 8-15) in U.S. ODs (89%) and MDs (68%) strongly/somewhat agree.6Xu L, Wang Y, Wang S, Wang Y Jonas JB. 'High Myopia and Glaucoma Susceptibility: The Beijing Eye Study. Ophthalmology, 2007;114(2):216-20.7Flitcroft DI. The complex interactions of retinal, optical, and environmental factors in myopia aetiology Prog Retin Eye Res. 2012;31(6):622-660.8Chen SJ, et al. Prevalence and associated risk factors of myopic maculopathy in elderly Chinese: the Shihpai eye study. Invest Ophthalmol Vis Sci. 2012;53(8):4868-4873.9Chen SJ, et al. High myopia as a risk factor in primary open angle glaucoma. Int J Ophthalmol. 2012; 5(6):750-753.10 Younan C, et al. Myopia and incident cataract and cataract surgery: the blue mountains eye study. Invest Ophthalmol Vis Sci. 2002;43(3625-3632).

About CooperVisionCooperVision, a division of CooperCompanies (NYSE:COO), is one of the world's leading manufacturers of soft contact lenses. The Company produces a full array of daily disposable, two-week and monthly contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism, presbyopia and childhood myopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visitwww.coopervision.com.

About CooperCompaniesCooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units,CooperVisionandCooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visitwww.coopercos.com.

Media Contacts

Consumer Media: EvolveMKD, [emailprotected] or +1-646-517-4220

Eyecare, Medical and Science Media: McDougall Communications,[emailprotected] or +1-585-478-4338 (mobile)

SOURCE CooperVision

https://coopervision.com

Visit link:
CooperVision Announces Sarah Michelle Gellar as Spokesperson to Increase Awareness of Myopia Management and the Brilliant Futures Program with MiSight...

Read More...

Our perfectly healthy daughter can no longer string a sentence together after being diagnosed with dementia – The Sun

Wednesday, September 2nd, 2020

A HEALTHY 11-year-old girl can no longer string a sentence together after being diagnosed with dementia.

Molly Ingham was diagnosed with a rare form of childhood dementia in May last year after she started to lose her eyesight, memory and mobility.

5

5

The normal outgoing little girl started having seizures when she was just six-years-old.

Batten disease robs children of their speech and sufferers of the disease rarely make it to adulthood.

Mum Adele Ingham, 39, said Molly can become confused because of the condition and now has to use a wheelchair as she no longer has any balance.

She said: "It's been devastating to watch the most outgoing little girl that could do everything every other six-year-old could do go into this situation.

It's soul destroying. It affects short term memory so she won't take in new things.

She started a special school last September and made lots of friends but she can't remember any of their names now.

What is Batten disease?

Batten disease, otherwise known as Neuronal Ceroid Lipofuscinoses, is a fatal disorder that affects the nervous system.

The condition, which typically begins in childhood, can manifest itself in vision problems and seizures.

It can then worsen, with children suffering from cognitive impairment, worsening seizures, and progressive loss of sight and motor skills.

It is often fatal by late teens or early 20s.

According to BDFA UK, an estimated 1 3 children are diagnosed with an infantile form of the disease each year, meaning there are probably between 15 and 30 affected children in the UK.

There are other variations of the genetic disease, with 14 strains so far diagnosed.

There is currently no cure

5

The family live in Stalybridge, Greater Manchester and Adele said Molly has started to ask her when she can go home, but she asks the question when they are already home.

She added: There's a lot of confusion.

"My dad died two and a half years ago and she still wants to go in when we drive past his flat.

She used to know every word to every Disney song now she can't even string a sentence together.

"She can't see anymore. I just bought her a new Olaf toy and she didn't know what it was until she felt his carrot nose.

5

Molly used to be able to ride scooters, go to the park and use the climbing frames - like any other child, but now things have changed.

"Everything just started becoming more difficult so now she's in a wheelchair because she's got no balance and she'll fall and hurt herself.

I might have only a few years left with her and that's being positive.

Adele said Molly was a perfectly healthy child until she turned six when teachers started to notice her zoning out and she began having seizures.

Soon after Molly was taken to see a paediatrician who suggested ADHD or a low IQ but after a second opinion, she was diagnosed with absence epilepsy until the condition progressed and her seizures became more frequent.

5

CLASS ACTBack-to-school with the Radfords as they share how to get 22 kids organised

Exclusive

ALL WHITEI wed in a 20 dress which I found stained on the shop floor - a wash sorted it

PLASTIC PRIVATESWe saved up for 'Barbie surgery' because we hated how we looked down below

FROZEN IN TIMEI've been looking after my '10-month-old' daughter for the last 19 years

NO KIDDINGI get viciously shamed for dumping my kids on my parents- but I need the break

THAT'S RADMum-of-22 Sue Radford jokes about Millie's 'mum tum' as they pack hospital bag

Adele worries she doesn't have much time left with Molly and is currently waiting to find out if her daughter has been accepted for a treatment trial in the US.

The mum and daughter would have to travel to Dallas to a centre called Taysha Gene Therapy.

The cost would be covered by the company as its a trial but the spaces are limited.

Adele added: "The treatment won't bring her eyesight back but it might help her to say the odd sentence instead of the odd word so there's still hope and a lot of fighting to do but I won't stop."

Read the original:
Our perfectly healthy daughter can no longer string a sentence together after being diagnosed with dementia - The Sun

Read More...

Parents plea for stem cell help to save life of daughter with rare blood disorder – Mirror Online

Wednesday, September 2nd, 2020

The parents of a girl battling a deadly blood disorder are begging people to join the stem cell donor register to save her life after her only match in the world pulled out at the last minute.

Evie Hodgson, eight, who suffers from aplastic anaemia, was due to have a bone marrow transplant this month but her donor backed out at the last possible moment.

Her mum, Tina, says the chances of finding another donor are so slim that doctors are now planning a different course of treatment. But, in future, a stem call transplant is Evies best hope of being cured.

The schoolgirl, from Whitby, North Yorks, was first taken to hospital with a rash and was diagnosed with aplastic anaemia in May.

After a global donor search was launched, a 10/10 match was found and the anonymous donor agreed to the procedure. In preparation, Evie had to have dental work and one of her ovaries was removed. But on August 14 the donor pulled out.

Tina, 37, who works at RAF Flyingdales, in Pickering, North Yorks, said: We were devastated, it was a huge blow. We have no idea why the donor changed their mind. Evie has already been through so much. She thought she had a donor and now she doesnt.

The donor pulling out is quite hard-hitting, but we want to raise awareness of the stem cell register. Its so easy to be a donor. Its just like giving blood, but you could save a childs life. Its so easy to join but only 1% of the UK population is registered.

Evie said: I need this transplant to save my life. Please sign the register to help.

Tina added: The condition Evie has is life-threatening. She wont survive without a transplant. We are desperately appealing for people to sign the stem cell register.

Evie was diagnosed with the condition after she developed a pin-prick rash on her back, which didnt fade. Tests revealed she had low blood platelet levels and she was told she needed a bone marrow transplant.

Aplastic anaemia is a rare life-threatening condition where the bone marrow fails to produce enough blood cells. Around 100-150 people are diagnosed in the UK each year.

Treatment can include immunosuppressants, chemotherapy, blood transfusions, or blood and bone marrow transplants.

Neither Tina, dad Andy, 49, or brother William, five, were a match and so an international search was launched.

Tina said: Our world crumbled when Evie was diagnosed. Evie knew shed need chemotherapy. She donated her hair to The Little Princess Trust, after making friends with poorly children who have lost all their hair.

Evie will be treated with immunosuppressants while the search for a donor continues.

Blood cancer charity Anthony Nolan is looking for stem cell donors between the ages of 16-30.

Research shows that younger donors result in better outcomes for patients.

To find out how to donate click here.

View original post here:
Parents plea for stem cell help to save life of daughter with rare blood disorder - Mirror Online

Read More...

Unraveling the use of CBD in veterinary medicine – Jill Lopez

Wednesday, September 2nd, 2020

It was about the 3rd week into Bastions recovery from his TPLO surgery and he was already having a rough time. Bastion was a gregarious yellow Labrador who had his injured stifle about 25 days ago. Fortunately, his family elected for him to have his stifle surgically reconstructed. Initially, he had recovered well from surgery. But one day in particular, he presented to the hospital because he had a brief setback. He was limping far more severely than what would be normally expected at this stage of recovery.

The osteotomy from his surgery had not yet completely healed and he was still in the middle of his prescribed 5 weeks of exercise strict restriction. His family was trying their best but Bastion wasnt having it. He was too active at home and his humans were growing frustrated. Anti-anxiety medications had been dispensed but they were not given. Instead, his family had decided to give him CBD oil at home. When I asked why the prescribed medications had not been given, the client responded, I found CBD oil at the local farmers market and I figured it would work just as well.

Like Bastion, an increasing number of pets are receiving cannabidiol (CBD) supplements. The popularity of CBD continues to rise and many clients are incorporating CBD as part of the medication protocol for their pets, either as an adjunct or, as alternative treatment option.

Perhaps the initial interest in the benefits of CBD can be traced back to 1998, or possibly earlier, when scientists at the National Institutes of Health discovered that CBD could protect cells from oxidative stress. These findings fueled interest in the human medical field and, in large part, that appeal has been transmuted into veterinary medicine. The regard for this molecule has risen to such levels that in many homes, CBD is being used as the sole treatment option for a variety of medical conditions.

Veterinarians are becoming more fluent in the fascinating pharmacology regarding the use of this phytocannabinoid. A recent survey indicated that most veterinarians (61.5%) felt comfortable discussing the use of CBD with their colleagues, but only 45.5% felt comfortable discussing this topic with clients.1 Furthermore, veterinarians and clients in states with legalized recreational marijuana were more likely to talk about the use of CBD products to treat canine ailments than those in other states.2 Lastly, CBD was most frequently discussed as a potential treatment for pain management, anxiety and seizures.1 At first glance, the use of CBD has tangential or limited relevance in the world of veterinary surgery. However, as one takes a closer look at the putative, and proven benefits, it is clear that we are just scratching the surface of its therapeutic benefits. This article takes a brief dive into the world of CBD and its promise in the field of veterinary surgery.

Pain

Whether you perform surgery within a specialty discipline (oncology, orthopedics, neurology, soft tissue surgery, mixed animal, oral/dental, etc), or surgery is only a small part of your general practice, every veterinarian endeavors to aggressively manage pain. The first choice for pain relief among many clinicians are the medications that have been more extensively studied including, but not limited to, anti-inflammatories, gabapentinoids, opioids, local anesthetics, and other analgesics (acetaminophen, amantadine, cerenia etc). These medications or a combination thereof, have been prescribed to treat pain from orthopedic surgery, soft tissue surgery, surgical neuropathic conditions, pain from intestinal surgery, to name just a few. In the most basic schema, pain is divided into four categories: nociceptive pain (a response to damaged tissue), neuropathic pain (a response to directly-damaged sensory or spinal nerves), centralized pain (the result of pain signals being improperly amplified), and inflammatory pain.1 Cannabinoids may have a role to play in mediating all four of these types of pain states. When tissue is damaged, histamine, serotonin, TNF-alpha, IL-1-beta, IL-6, and Il -17 6, and interleukin 17 are released.2 Cannabinoids bind to the CB1 receptors and attenuate the pain signal by slowing down the release of those neurotransmitters.3 This process can take place locally or in the central nervous system.3 Cannabinoids have also been shown to inhibit the release of GABA, a well known neurotransmitter associated with pain.3 Although there is a paucity of clinical research on the use of CBD to treat postoperative pain in the veterinary medical setting, there has been heartening research conducted in humans. Indeed, National Academies of Sciences, Engineering, and Medicine concluded that there is, substantial evidence that cannabis is an effective treatment for chronic pain in adults.

Opioids have long been the go to option, or cornerstone of pain management, however, the potential for the adverse events associated with the use of opioids in veterinary patients is universally accepted.38 I have seen how distressing it can be for a family to see their pet experiencing any of the unpleasurable side effects of opioids including urine retention, delayed bowel movements, whining, panting, disorientation, or other manifestations of dysphoria. Those are just some of the challenges that clinicians face when using opioids for chronic pain management. Considering the ongoing consequences of the opioid epidemic, there is a search for pain management solutions that are innovative, prone to less adverse events, and are more effective. As the scientific community begins to evaluate the evidence for use of CBD , it is clear that more research is needed.

Anecdotal reports of CBDs efficacy as a pain reliever are ubiquitous but more are turning to scientific data for evidence of CBDs efficacy. A study in 2020 evaluating effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients found that over half of chronic pain patients (53%) reduced or eliminated their opioids within 8 weeks after adding CBD-rich hemp extract to their regimens.5 Almost all CBD users (94%) reported quality of life improvements.5 And in a recent study evaluating orally consumed cannabinoids for long-lasting relief of allodynia in a mouse model, found that cannabinoids reduced hyperalgesia and a similar effect was not found with morphine.4 Mouse vocalizations were recorded throughout the experiment, and mice showed a large increase in ultrasonic, broadband clicks after sciatic nerve injury, which was reversed by THC, CBD, and morphine.4 The study demonstrated that cannabinoids provide long-term relief of chronic pain states.4 If research shows that use of cannabinoids in animals, specifically, CBD, can help to decrease the use of opioids for pain management, that would help make more animals comfortable and potentially help to fight the tragic epidemic of human prescription opioid abuse. Further research is needed in a variety of species, specifically, both the canine and feline species.

Bone Healing

Both general veterinary practitioners and veterinary surgeons commonly diagnose and treat fractures. A large retrospective study of fracture incidence in dogs in North America has not been published since 1994; however, the findings from that study are still informative regarding the frequency of bone injuries. That study demonstrated that approximately 24% of all patients in the population studied over a 10 year period were affected by a disorder of the musculoskeletal system, with fractures contributing the largest proportion (over 29%) of all of the diagnosis of the appendicular skeletal system.7 Although that research is dated, the conclusions from this study - at the very least, indicate that fractures are commonplace in the clinical veterinary setting.7 Fracture repair has gradually become more straightforward due to improvements in technology. Because of these innovations, speciality surgeons and general practitioners who repair fractures have begun to see better surgical outcomes. So whether you primarily stabilize fractures with implants, or if external coaptation of fractures with the intention to refer (or perhaps as the primary means of fixation) is your treatment of choice, all veterinary practitioners aim to help fractured bones heal quickly. Despite these technological improvements, bone healing can be protracted or non existent with some fractures. There are a variety of options at a veterinarians disposal to kick-start the healing process but perhaps in the near future, CBD may be added to that armamentarium. The effect of CBD in fracture healing has been investigated evaluating bone callus formation in femur fractures in a rat model.8 The findings demonstrated enhanced biomechanical properties of healing fractures in those given CBD compared with a control group.8 This effect was not found in those only given 9-THC. Moreover, the bone forming effects (osteogenic) of CBD were weakened when test subjects were given equal amounts of CBD and 9-THC.6 Another in vivo research study indicated that when CBD is incorporated into a surface that promotes bone growth (osteoconductive scaffold) it can stimulate stem cell migration and osteogenic differentiation.9 Further studies are needed to better evaluate the role of CBD in healing and bone metabolism of companion animals so that these findings can be applied in the clinical setting.

Additionally, cannabis has been shown to be a useful addition in treatment plans optimized to improve bone health in laboratory studies. A study endeavored to more closely understand the role of CB2 receptors in maintaining bone health. CB2 receptors in bone cells have been linked to maintaining bone density and stimulating growth, and may therefore have a part in reversing the effects of osteoporosis.10 One study evaluating role of CB2 receptors, found that in mice whose genes had been altered to remove the CB1 or CB2 receptors, those that developed signs of bone weakness that were far more pronounced than those in the control group.12 Another study in 2009, investigated the relationship between CB2 expression and bone disease in humans. The study found that people with dysfunctional CB2 receptors to have significantly weaker hand bones.11

Arthritis

Osteoarthritis (OA) affects many dogs, large and small. Most often, OA is the consequence of a developmental orthopedic disease that often affects a single joint or a pair of joints, and, less often, affects multiple joints. It is axiomatic that Mother Nature likes symmetry thus developmental orthopedic diseases frequently affect both left and right joints. For example, hip dysplasia is reportedly bilateral in >60% of affected dog,s13 and elbow dysplasia is bilateral in approximately 50% of affected dogs.14 Osteoarthritis occurs secondary to a myriad of primary orthopedic conditions that affect a variety of joints including: the hip (most common causes of OA in the hip: hip dysplasia, Perthes disease); stifle (patellar luxation, cranial cruciate ligament disease, osteochondritis dissecans [OCD]); elbow (elbow dysplasia, elbow OCD, fragmentation of the medial coronoid process, incomplete ossification of the humeral condyle); shoulder (shoulder OCD, developmental shoulder subluxation); tarsus (OCD of the talus), and carpus (carpal laxity, carpal subluxation secondary to chondrodystrophy); and metacarpophalangeal (MCP) and metatarsophalangeal (MTP) joint degenerative osteoarthritis (digital osteoarthritis) .

Cannabinoids were found to treat pain secondary to inflammation in a variety of studies on humans. Some of the most compelling research has shown that cannabis can reduce the inflammation in the joint caused in human patients diagnosed with immune mediated arthritis.15 One study found that cannabinoids could simultaneously reduce the secretion of cytokines involved in inflammation from one type of TH immune cells, which were being under-produced, while also increasing their numbers to correct their scarcity.15 Furthermore in a study in 2003, researchers found that plant-based cannabinoids could suppress the expression of interleukin-1betaone of the most prominent markers for inflammation in patients with rheumatoid arthritisby as much as 50%.16 And finally, in 2006, transdermal applications of CBD were shown to decrease biomarkers that can contribute to neurogenic inflammation in a sample of arthritic rats. 17

A report published in the journal of PAIN, lead by researchers at Baylor College of Medicine revealed the results of a large, double blinded, placebo controlled study on the positive effects CBD had in the fight against osteoarthritis.18 The study was designed with two main goals: The first portion of the research studied the effect CBD had on the inflammatory molecules and cells in mice.18 The second portion of the study, investigated whether CBD improved the quality of life in dogs diagnosed with osteoarthritis. In lab tests and in mouse models, CBD significantly decreased the production of natural chemicals that promote inflammation and it increased the natural chemicals that fight inflammation.18 Essentially, what they saw was a drop in proinflammatory cytokines and an increase in anti-inflammatory cytokines. 18 For dogs with osteoarthritis, CBD significantly decreased pain and increased mobility in a dose-dependent fashion. Importantly, A lower dose of liposomal CBD was as effective as the highest dose of nonliposomal CBD, indicating that the effect of CBD was quicker and more effective when CBD was delivered encapsulated in liposomes than without.18 Blood samples indicated no significant harmful side effects, or adverse events, over the 4-week analysis period.18 Although this study is very promising and it supports the safety and therapeutic potential of hemp-derived CBD for relieving arthritic pain in dogs, it is important to consult with your pets veterinarian before giving any supplement or medication.

In the veterinary population, use of cannabidiol and other alternative treatments may have the potential to obviate the need for other medications, and thus spare patients from adverse effects associated with their use. More likely, the use of cannabinoids could be additive or synergistic in a multimodal treatment strategy and could increase quality-of-life issues associated with painful arthritic conditions.

Intervertebral Disk Disease

As our patients age, discs in the spine also undergo degenerative changes. Thus, degeneration of intervertebral discs is evitable. This process of degeneration is multifactorial process and it involves hypoxia, inflammation, neoinnervation, accelerated catabolism, and reduction in water and glycosaminoglycan content.39 The magnitude and severity of disc degeneration can vary widely between patients. The most common locations of clinically relevant disc disease are located in the cervical spine, thoracolumbar spine, and the lumbosacral spine.40 Although there are various manifestations of disc disease, broad classifications of Hansen Type I and Type II are typically used to describe the condition. In short, disc material may either extrude (acute herniations) or protrude (chronic herniations), both of which compress the spinal cord which ultimately can cause pain, paresis, paralysis and other neurological deficits.40 The prevalence of thoracolumbar disc disease dogs has been estimated at 3.5%.40 Depending on the neurologic examination, diagnosis, severity, prognosis, and other factors, surgery may be recommended to decompress the spinal cord.

After surgical decompression, there are a host of challenges that the the patient, the family, and the surgeon, may have to work through including a potentially protracted recovery, recurrence of neurological signs, post surgical pain, spinal instability, urinary disorders, (cystitis, urinary tract infection, urinary retention, micturition disorders), ascending myelomalacia, and others.41 Could CBD play a part in helping to improve those affected by disc disease pre-, intra-, or post-operatively and what types of spinal disorders could benefit from CBD? A study conducted on the use of CBD in mice with degenerative disc disease showed promise in mitigating the effect of disc damage and wear.19 Instead of being ingested orally, CBD was injected at the site of the disc. Researchers investigated the effects of cannabidiol intradiscal injection using a combination of MRI and histological analyses.19 A puncture was created in the disc and then CBD was injected into the disc (30, 60 or 120 nmol) shortly after.19 The effects of intradiscal injection of cannabidiol were analyzed within 2 days by MRI.17 Fifteen days later, the group that received cannabidiol 120 nmol was resubmitted to MRI examination and then to histological analyses after the cannabidiol injection.19 What they found was that cannabidiol significantly decreased the effects of disc injury induced by the needle puncture.19 These results suggest that this compound could be useful in the treatment of intervertebral disc degeneration perhaps using a novel route of administration.

Unfortunately, the exact mechanism for how CBD oil helped protect disc damage is still being investigated. The hope is that the neuroprotective properties of cannabidiol can also be found in the study of canine and feline disc disease to ultimately improve functional recovery.

References:

Kogan L, Schoenfeld-Tacher R, et al. US Veterinarians' Knowledge, Experience, and Perception Regarding the Use of Cannabidiol for Canine Medical Conditions. Front Vet Sci. 2018;5:338.

Abd-Elsayed A., Deer T.R. (2019) Different Types of Pain. In: Abd-Elsayed A. (eds) Pain. Springer, Cham. https://doi.org/10.1007/978-3-319-99124-5_3

Manzanares J, Julian MD, Carrascosa A. Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes Curr Neuropharmacol. 2006 Jul; 4(3): 239257.

Abraham AD, Leung EJ, Brenden A, Wong BA, Rivera ZM, Kruse LC, et al. Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain. 2020 Jun;45(7):1105-1114. doi: 10.1038/s41386-019-0585-3. Epub 2019 Dec 7.

Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020 Jan;132(1):56-61. doi:10.1080/00325481.2019.1685298. Epub 2019 Nov 12.

Abraham AD, Leung EJ, Wong BA, Rivera ZM, Kruse LC, Clark JJ, Land BB. Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain. Neuropsychopharmacology. 2020: 45:11051114.

Johnson, J., Austin, C., & Breur, G. Incidence of Canine Appendicular Musculoskeletal Disorders in 16 Veterinary Teaching Hospitals from 1980 through 1989. Veterinary and Comparative Orthopaedics and Traumatology, 07(02), 5669. (1994). doi:10.1055/s-0038-1633097

Kogan NM, Melamed E, Wasserman E. Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts J Bone Miner Re. 2015 Oct;30(10):1905-13. doi: 10.1002/jbmr.2513. Epub 2015 May 10.

Kamali, A., Oryan, A., Hosseini, S., Ghanian, M. H., Alizadeh, M., Baghaban Eslaminejad, M., & Baharvand, H. Cannabidiol-loaded microspheres incorporated into osteoconductive scaffold enhance mesenchymal stem cell recruitment and regeneration of critical-sized bone defects. Materials Science and Engineering: (2019). C, 101, 6475. doi:10.1016/j.msec.2019.03.070

Bab I, Zimmer A. Cannabinoid Receptors and the Regulation of Bone Mass. British Journal of Pharmacology. 2007 153:182-188 doi:10.1038/sj.bjp.0707593

I. Idris, A. Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies. Current Neuropharmacology. 2010. 8(3), 243253. doi:10.2174/157015910792246173

Meliha Karsak et al. The Cannabinoid Receptor Type 2 (CNR2) Gene Is Associated with Hand Bone Strength Phenotypes in an Ethnically Homogeneous Family Sample. Human Genetics. 2009. 5:629-36 doi:10.1007/s00439-009-0708-8.

Loder, R. T., & Todhunter, R. J. The Demographics of Canine Hip Dysplasia in the United States and Canada. Journal of Veterinary Medicine. 2017 115. doi:10.1155/2017/5723476

ONeill DG, Brodbelt DC, Hodge R,. Church DB, Meeson RL. Epidemiology and clinical management of elbow joint disease in dogs under primary veterinary care in the UK. Canine Medicine and Genetics. 2020 volume 7:1

Susan H. Pross et al. Differential Suppression of T-cell Subpopulations by THC (delta-9- tetrahydrocannabinol). International Journal of Immunopharmacology 12, no. 5 (1990): 539-44. doi:10.1016/0192-0561(90)90118-7

Robert B. Zurier et al. Suppression of Human Monocyte Interleukin-1 Production by Ajulemic Acid, a Nonpsychoactive Cannabinoid. Biochemical Pharmacology. 2003 4:649-55. doi:10.1016/s0006-2952(02)01604-0.

D.c. Hammell et al. Transdermal Cannabidiol Reduces Inflammation and Pain-related Behaviours in a Rat Model of Arthritis. European Journal of Pain. 2015 6:936-48. doi:10.1002/ejp.818

Verrico, C. D., Wesson, S., Konduri, V., Hofferek, C. J., Vazquez-Perez, J., Blair, E., Halpert, M. M. A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. 2020. Pain. doi:10.1097/j.pain.0000000000001896

Silveira, J. W., Issy, A. C., Castania, V. A., Salmon, C. E. G., Nogueira-Barbosa, M. H., Guimares, et al. Protective Effects of Cannabidiol on Lesion-Induced Intervertebral Disc Degeneration. 2014. PLoS ONE 9:12 doi:10.1371/journal.pone.0113161

Yam, M., Loh, Y., Tan, C., Khadijah Adam, S., Abdul Manan, N., & Basir, R. . General Pathways of Pain Sensation and the Major Neurotransmitters Involved in Pain Regulation. International Journal of Molecular Sciences. 2018 19(8), 2164. doi:10.3390/ijms19082164

Costigan, M., Scholz, J., & Woolf, C. J. Neuropathic Pain: A Maladaptive Response of the Nervous System to Damage. Annual Review of Neuroscience. 2009 32(1), 132. doi:10.1146/annurev.neuro.051508.135531

Arora A, Taliyan R, Sharma PL. Ameliorative Potential of Cannabis Sativa Extract on Diabetes Induced Neuropathic Pain in Rats. International Journal of Pharmaceutical Sciences and Research 1. 2010 https://www.researchgate.net/publication/216536386_Ameliorative_potential_of_cannabis_sativa_extract_

Mark S. Wallace et al., Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. 2015. Pain 16(7): 616-27 doi:10.1016/j.jpain.2015.03.008.

Gruen, M. E., Roe, S. C., Griffith, E., Hamilton, A., & Sherman, B. L.. Use of trazodone to facilitate postsurgical confinement in dogs. Journal of the American Veterinary Medical Association. (2014) 245(3), 296301. doi:10.2460/javma.245.3.296

Serra, G., & Fratta, W. A possible role for the endocannabinoid system in the neurobiology of depression. Clinical Practice and Epidemiology in Mental Health. 2007. 3(1), 25. doi:10.1186/1745-0179-3-25

Kim, E. J., Pellman, B., & Kim, J. J. Stress effects on the hippocampus: a critical review. Learning & Memory. 2015. 22(9), 411416. doi:10.1101/lm.037291.114

Demirakca, T., Sartorius, A., Ende, G., et al. Diminished gray matter in the hippocampus of cannabis users: Possible protective effects of cannabidiol. 2010. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2010.09.020

Mateus M. Bergamaschi et al. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Nave Social Phobia Patients. Neuropsychopharmacology. 2011 36(6):1219-26 doi:10.1038/npp.2011.6.

Jos Alexandre S Crippa et al. Neural Basis of Anxiolytic Effects of Cannabidiol (CBD) in Generalized Social Anxiety Disorder: A Preliminary Report. Journal of Psychopharmacology. 2010. 25: 1doi:10.1177/0269881110379283.

National Academies of Sciences, Engineering, and Medicine, 120.

Zieba, J., Sinclair, D., Sebree, T., Bonn-Miller, M., Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP1-independent mechanism. Pharmacology Biochemistry and Behavior. 2019. doi:10.1016/j.pbb.2019.05.002

Pamplona, F. A., da Silva, L. R., & Coan, A. C. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. 2018. Frontiers in Neurology, 9. doi:10.3389/fneur.2018.00759

Palmieri B, Laurino C, Vadal M. A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. Mar-Apr 2019;170(2):e93-e99. doi: 10.7417/CT.2019.2116.

Sangiovanni, E., Fumagalli, M., Pacchetti, B., Piazza, S., et al.. Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury. (2019). Phytotherapy Research. doi:10.1002/ptr.6400

B. Van Klingeren and M. Ten Ham. Antibacterial Activity of 9-tetrahydrocannabinol and Cannabidiol. 1976. 42(1-2): 9-12 doi:10.1007/bf00399444.

Giovanni Appendino et al. Antibacterial Cannabinoids From Cannabis Sativa: A StructureActivity Study. 2008. Journal of Natural Products 71(8):1427-430, doi:10.1021/np8002673

McIver, V., Tsang, A., Symonds, N., Perkins, N., et al. Effects of topical treatment of cannabidiol extract in a unique manuka factor 5 manuka honey carrier on second intention wound healing on equine distal limb wounds: a preliminary study. 2020. Australian Veterinary Journal. doi:10.1111/avj.12932

White, D. M., Mair, A. R., & Martinez-Taboada, F. Opioid-free anaesthesia in three dogs. Open Veterinary Journal. 2017 7(2), 104. doi:10.4314/ovj.v7i2.5

Hansen T, Smolders LA, Tryfonidou MA, et al: The Myth of Fibroid Degeneration in the Canine Intervertebral Disc: A Histopathological Comparison of Intervertebral Disc Degeneration in Chondrodystrophic and Nonchondrodystrophic Dogs. Vet Pathol 2017 Vol 54 (6) pp. 945-952.

40. Jeffery ND, Levine JM, Olby NJ, et al: Intervertebral disk degeneration in dogs: consequences, diagnosis, treatment, and future directions. J Vet Intern Med 2013 Vol 27 (6) pp. 1318-33.

41. Balducci F, Canal S, Contiero B, et al: Prevalence and Risk Factors for Presumptive Ascending/Descending Myelomalacia in Dogs after Thoracolumbar Intervertebral Disk Herniation. J Vet Intern Med 2017 Vol 31 (2) pp. 498-504.

See the article here:
Unraveling the use of CBD in veterinary medicine - Jill Lopez

Read More...

Global Stem Cell Banking Market with Covid-19 Effect Analysis, Growth, Research Findings, Type, Application, Element Global Trends and Forecast to…

Wednesday, September 2nd, 2020

Global Marketers offers newly published research report titled, Stem Cell Banking Market .This report focuses on delivering the up-to-date and latest growth opportunities, 360-degree market overview, and statistical data of Stem Cell Banking industry. The report highlights industry overview, growth trajectory, market dynamics, market share analyzed in detail this report. It furthermore gives a total synopsis of the market over the globe, including definitions, and applications. Moreover, the improvement plans and policies concerning the market have been discussed in the statistical surveying report, alongside the cost structures and production processes.

Get Free Sample copy @ https://www.globalmarketers.biz/report/life-sciences/global-stem-cell-banking-market-report-2019,-competitive-landscape,-trends-and-opportunities/135432#request_sample

The most significant players coated in global Stem Cell Banking Market report:

CrioestaminalRMS RegrowLifeCellBoyalifeVcanbioKrioEsperiteBeikebiotechCryo-cellPacifiCordCryo StemcellCells4lifePBKM FamiCordStemade BiotechCellsafe Biotech GroupAmericordViaCordCordlife GroupCCBCFamilycordCBRStemCyte

The research report also studied the key players operating in the global Stem Cell Banking Market. It has evaluated and elucidated the research and development statuses of these companies, their financial outlooks, and their expansion plans for the prediction period. This research report also includes the list of planned initiatives that clearly explain the achievements of the Stem Cell Banking companies in the recent past.

Global Stem Cell Banking Market Regions Analysis:

Regional analysis is a highly all-inclusive part of this report. The geographical analysis of the global Stem Cell Banking Market has been showed in four major regions, namely the Asia Pacific, North America, Europe, and the rest of the world containing Latin America and the Middle East and Africa.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.globalmarketers.biz/discount_inquiry/discount/135432

The competitive landscape of the Stem Cell Banking market is described in terms of the players and their statistics. The research on the Stem Cell Banking will be applicable to investors, business owners, industry experts, and various c level peoples. The report also creates a clear picture of the various factors that will drive the Stem Cell Banking Market in the years to come. This report offers a SWOT analysis of the global market.

The Type Coverage in the Market are:

Placental Stem Cells (PSCs)Human Embryo-derived Stem Cells (HESCs)Bone Marrow-derived Stem Cells (BMSCs)Adipose Tissue-derived Stem Cells (ADSCs)Dental Pulp-derived Stem Cells (DPSCs)Other Stem Cell Sources

The Application Coverage in the Market are:

Personalized Banking ApplicationsClinical ApplicationsHematopoietic DisordersAutoimmune DisordersOther DiseasesResearch ApplicationsDisease Treatment StudiesLife Science ResearchDrug Discovery

The Stem Cell Banking market analysts and researchers have done wide analysis of the global Stem Cell Banking industry with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided exact market data and worthwhile recommendations with an aim to help the key players to gain an insight into the overall current and future market scenario.

The study analyses the following key business aspects:

Table ofContents

Global Stem Cell Banking Market Research Report 2020-2026

Chapter 1 Stem Cell Banking Market Overview

Chapter 2 Global Economic Impact on Stem Cell Banking Industry

Chapter 3 Global Market Competition by Key Vendors

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Production, Revenue (Value), Price Trend by Type

Chapter 6 Global Stem Cell Banking Market Analysis by Application

Chapter 7 Manufacturing Cost Analysis of Stem Cell Banking Market

Chapter 8 Marketing Strategy Analysis, Traders

Chapter 9 Stem Cell Banking Market Factors Analysis

Chapter 10 Global Stem Cell Banking Market Forecast up to 2026

Get Full Report With Complete TOC @ https://www.globalmarketers.biz/report/life-sciences/global-stem-cell-banking-market-report-2019,-competitive-landscape,-trends-and-opportunities/135432#table_of_contents

Go here to see the original:
Global Stem Cell Banking Market with Covid-19 Effect Analysis, Growth, Research Findings, Type, Application, Element Global Trends and Forecast to...

Read More...

Plasma Therapy Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2025 – StartupNG

Wednesday, September 2nd, 2020

The Plasma Therapy market research report added by Market Study Report, LLC, is an in-depth analysis of the latest trends persuading the business outlook. The report also offers a concise summary of statistics, market valuation, and profit forecast, along with elucidating paradigms of the evolving competitive environment and business strategies enforced by the behemoths of this industry.

The Plasma Therapy market report provides with a broad perspective of this business space and contains crucial insights such as current and predicted remuneration of the industry, in consort with its size and valuation over the estimated timeframe.

Request a sample Report of Plasma Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2448306?utm_source=scientect.com&utm_medium=AG

The study assesses the key factors that are positively affecting the industry landscape based on revenue generated as well as market growth. Additionally, the document analyzes the current trends that define this market while evaluating the challenges & limitations as well as the growth factors of this domain.

Key aspects of Plasma Therapy market report:

Regional analysis of Plasma Therapy market:

Plasma Therapy Market Segmentation:

Product types and application scope of Plasma Therapy market:

Product landscape:

Product types:

Key factors highlighted in the report:

Application Landscape:

Application segmentation:

Details specified in the document:

Additional information enlisted in the document:

Ask for Discount on Plasma Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2448306?utm_source=scientect.com&utm_medium=AG

Competitive arena of the Plasma Therapy market:

Key players in the Plasma Therapy market:

Major aspects enlisted in the report:

Report Objectives:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-plasma-therapy-market-growth-status-and-outlook-2020-2025

Some of the Major Highlights of TOC covers:

Plasma Therapy Regional Market Analysis

Plasma Therapy Segment Market Analysis (by Type)

Plasma Therapy Segment Market Analysis (by Application)

Plasma Therapy Major Manufacturers Analysis

Related Reports:

1. Global Induced Pluripotent Stem Cells (iPSCs) Market Growth (Status and Outlook) 2020-2025This report categorizes the Induced Pluripotent Stem Cells (iPSCs) market data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors Analysis.Read More: https://www.marketstudyreport.com/reports/global-induced-pluripotent-stem-cells-ipscs-market-growth-status-and-outlook-2020-2025

2. Global Ergothioneine (EGT) Market Growth (Status and Outlook) 2020-2025Ergothioneine (EGT) Market report covers the market landscape and its growth prospects over the coming years, the Report also brief deals with the product life cycle, comparing it to the relevant products from across industries that had already been commercialized details the potential for various applications, discussing about recent product innovations and gives an overview on potential regional market.Read More: https://www.marketstudyreport.com/reports/global-ergothioneine-egt-market-growth-status-and-outlook-2020-2025

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See the original post:
Plasma Therapy Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2025 - StartupNG

Read More...

What are T-cells and why have they become a political football? – New Scientist News

Wednesday, September 2nd, 2020

By Clare Wilson

NIH/National Institute of Allergy and Infectious Diseases

Throughout the coronavirus pandemic there have been fierce debates over the science when to lock down, whether face coverings help and whether children are less susceptible, for example. The latest row is over whether we have been ignoring a crucial part of our immune response to the virus: T-cells.

This matters because if people have more immunity to the virus than we thought, then perhaps wecould abandon some covid-19 countermeasures. This was the case made by US President DonaldTrumps newest adviser oncovid-19, Scott Atlas at Stanford University in California. It has also been championed by others who argue against lockdowns. Is there any truth to the idea?

The immune system has two main arms to fight off pathogens such as the coronavirus. The one we hear most about consists of antibodies, small molecules that can recognise specific pathogens and target them for destruction.

Advertisement

Antibodies against the coronavirus can be measured in the blood and so surveys quickly began to gauge the proportion of people who have them. But even in places hit hard by the pandemic, antibody levels arent high enough to give herd immunity, which occurs when enough people are immune to the virus that it can nolonger easily spread.

Researchers have estimated that 65 per cent of a population would need to be immune to achieve herd immunity, based on how contagious the virus is. In London, antibody levels were about 10 per cent between 26 April to 9 August. For England as a whole, as with many European countries, it is insingle digits.

These levels are widely taken as indicating how many people have been infected by the coronavirus. But the picture is more complex than this because of the second arm of our immune system, T-cells. Antibodies are sometimes seen as more important because they can stop viruses from entering the body. But once viruses make it inside, only T-cells can kill infected cells.

It takes a few days to obtain results for tests of T-cell activity against the coronavirus, compared with as little as 90 minutes for antibody tests, but a few groups have been testing on a small scale. They have found T-cells that react to the coronavirus in 10 to 50 per cent of people tested.

That doesnt necessarily mean that up to half the population isimmune to covid-19, says Alessandro Sette at the La Jolla Institute for Immunology in California. Some of these studies, including one by Sette and his colleagues, looked at blood donations given before the current pandemic, to test for pre-existing immunity to the coronavirus. Others examined samples from people with covid-19.

The most likely explanation isthat the pre-pandemic blood samples that tested positive were from people who had previously caught milder coronaviruses, such as the ones that cause colds, and their T-cells are reacting to the one that causes covid-19. It is probable, although by no means definite, that such people would get less sick with covid-19, but they could still get infected and pass it on to others, says Sette.

However, a Swedish study that tested about 200 people, including some known to have had covid-19 and their family members, found that those who had been sickest with covid-19 had more T-cell activity. This suggested it was directed against the current coronavirus, not old ones, says Marcus Buggert at the Karolinska Institute in Stockholm, who worked on the study. But we cant say every single T-cell was induced by this new virus, he says.

As with antibodies, it is unclear how long T-cell immunity will last. I have seen [people] using our data to say we should open up society. I definitely do not want that, says Buggert.

T-cells could explain some puzzling anomalies in antibody testing. We have had people with confirmed cases of covid-19. Their antibody tests have come back negative, but their T-cells tested positive. That suggests antibody tests are not telling us the whole picture, says James Hindley at UKfirm Indoor Biotechnologies, which has developed a relatively fast and simple T-cell test.

The firms work hasnt yet beenpublished, and its test has sofar only been used on about 100people. But Hindleys team has found a few people testing positive for T-cell activity whose spouse had confirmed covid-19, yet they themselves somehow avoided it, as far as they know. It raises the question of whether the T-cells kept the virus at bay, says Hindley.

It is unlikely that questions such as these will be resolved until T-cell testing becomes much more common. Until then, says Hindley, the growing body of T-cell work should be seen as cause for hope but not complacency.

Sign up to our free Health Check newsletter for a round-up of all the health and fitness news you need to know, every Saturday

More on these topics:

Read the rest here:
What are T-cells and why have they become a political football? - New Scientist News

Read More...

Talk with the Doc: The human immune system and ‘herd’ immunity – Marquette Mining Journal

Wednesday, September 2nd, 2020

With the current corona virus pandemic in the United States and world wide, there are many scientists working very diligently to come up with an effective vaccine to reduce the significant healthcare impact of this virus. They are also evaluating and working on the various treatments options for the many people who have been infected with this virus. Therefore, I believe it is timely at this time to again review the importance of our human immune system and vaccines that can provide herd immunity.

Human Immune System The overall function of our human immune system is to prevent or limit infection. The primary job of our immune system is to distinguish between our normal, healthy cells and possible other dangerous cells, such as viruses and bacteria that may come into our blood stream. Our immune system is always on duty to look for and recognize these possible infectious viruses and bacteria. The immune system looks closely at these potentially infectious cells to do all it can to prevent us from getting an infection.

Know that we rely on our immune system every day to help us fight off infections and keep us healthy. Our immune system contains numerous cell types that either circulate throughout the body or reside in our particular body tissues. Each cell type plays a unique role, with different ways of performing their function to fight off infections. Further, many world wide medical and scientific researchers are working diligently at this time to develop a vaccine to effectively prevent the corona virus.

Vaccines When we receive a vaccine in our body, our powerful human immune system notes that this is a foreign potentially dangerous substance and promptly begins to make antibodies to fight it off. Here is the true positive impact of vaccines on USA health today. Our federal government reports that because of USA children receiving the recommended childhood immunizations, around 20 million illnesses and more than 40,000 deaths are prevented, resulting in approximately $70 billion in health care savings. Vaccinations are effective primarily due to two factors. First, once a person is immunized against a specific disease producing organism, the rate of that disease, as well as its associated asymptomatic carrier state, is decreased. Second, when a large population is immunized, unvaccinated individuals may also benefit from a reduced risk of exposure to these disease producing organisms.

Herd Immunity Herd immunity is a form of indirect protection from infectious disease that occurs when a sufficient percentage of a population has become immune to an infection, whether from vaccination or from previous infections, thereby reducing the likelihood of infection for individuals who lack immunity. Following is a brief review of the two ways we can receive herd immunity.

So, how do we achieve herd immunity? There are two ways this can happen. 1. We can develop resistance naturally. When our body is exposed to a virus or bacteria, it makes antibodies to fight off the infection. When we recover, our body keeps these antibodies, and then our body will defend against another infection of this type. 2. Vaccines will also build herd immunity. They make your body think a virus or a bacteria has infected it. You dont get sick, but your immune system still makes protective antibodies. The next time your body meets that bacteria or virus, it is ready to fight it off. Perhaps the greatest example the effectiveness of vaccines is the fact that the Salk vaccine essentially eliminated polio in the United States.

EDITORS NOTE: Dr. Jim Surrell is the author of The ABCs For Success In All We Do and the SOS (Stop Only Sugar) Diet books.Contact Dr. Surrell by email at sosdietdoc@gmail.com.

Today's breaking news and more in your inbox

Read more here:
Talk with the Doc: The human immune system and 'herd' immunity - Marquette Mining Journal

Read More...

Eat Protein to Boost Your Immune System. Here’s How Much You Need – The Beet

Wednesday, September 2nd, 2020

When you think about protein, you probablyworry about getting enough to repair muscle tissue after a tough workout, to help your body build lean, strong muscles and lose weight while boosting your natural calorie burn. All that's true but protein also serves another critical function in the body: It helps power your immune system, stoking the cells that you need to fight off infection, both bacterial and viral, and keep your guard up against illness of all kinds.

Protein plays an important role in powering your body'sT-cells, the agentsthat go out and attack opportunistic invaders that can get into your bloodstream and cause infection, and if you lack adequate protein intake, it can impair immune reaction, studies have found. Adiet low in protein leavesyou open to fatigue, weakness, and low immune response, all the more reason you need to get your essential amino acids from the food you eat (which is better than supplements). Meanwhile, your body is just as happy to get its full complement of protein from plants.

Proteins make up the framework of your cells, including the cells of the immune system and just about every other. But you don't have to worry if you're eating mostly plant-based foods, since the source of protein is less important than getting a full array of essential amino acids, specifically the 9 ones your body can't make enough of on its own.

In rare cases of protein deficiency (very seldom in a healthy US population other than those patients being treated with chemo), your immune system can stall, but the more frequent scenario of eating too much protein can also dampen downyour immune system by overtaxing your kidneys, which can't flush it fast enough. Americans, while obsessed with eating enough protein, are likely to eattoo much, according to experts. On average weeat up to twice as much protein as they need, about 100 grams a day when 60 is closer to the average that most people should get. The latest studies show thatthe right amount of protein is critical for your immune system to be healthiest.

In hospitals where patients lack appetite and treatments can zap their immunity, especially when someone is on chemotherapy for cancer, they are often given arginine, an amino acid that contains the most nitrogen of any, and has been shown to help boost immunity and speed up healing, according to the latest research.Another amino acid, glutamine, travels in your blood cells to offer your intestinal cells curative effects, which can prevent microbial contamination from the food you eat. But for most of us, supplements are not the answer, a healthy diet with a variety of vegetables, grains, legumes, fruits, nuts, and seeds will do it.

"Most healthy adults should aim to get around .8 to 1.2 grams of protein per kilogram of body weight per day, or roughly 55 to 80 grams of protein for a 150 lb adult," saysKatie Mikus, Manager of Scientific Affairs for Glanbia,which makes a plant-basedsupplementcalled Gold Standard 100% Plant with 24 grams of protein and4 Grams of Naturally Occurring Glutamine. For the right amount of protein for your size, activity level, age, and gender, check out this handy calculator here."Those looking to build or maintain muscle mass may wish to consume as much as 2.2 grams of protein per kilogram body weight per day," she adds.

When it comes to protein quality, look for protein sources that are easily digested and contain all 9 essential amino acids. Essential amino acids are those that must be consumed through whole foods or supplements because the body cannot make sufficient quantities to meet demand.

The richest plant sources of proteins tend to be legumes like soybeans, chickpeas, and beans and whole grains like quinoa and amaranth as well as certain vegetables, nuts, seeds and fruit. For a complete list of the best sources of plant-based proteins, see the 20 top vegetables for protein, compiled by The Beet.

Many plant-based proteins are "incomplete,"meaning they lack one or more of the 9 essential amino acids your body can't make on its own. "Complimentary incomplete plant proteins can be combined to create a complete protein. For example, grains tend to be low in lysine and high in methionine and cysteine, whereas legumes tend to be high in lysine and low in methionine and cysteine," Mikus explains. "So combining rice and beans will give you a complete protein, or peanut butter and whole wheat bread are examples of complementary proteins that make a complete protein when eaten together."

Complimentary plant proteins dont necessarily have to be eaten together as long as you consume protein from a variety of plant sources throughout the day. For more on how to get your complete proteins, see The Beet's story on perfect plant-based proteins.

But rather than worry about getting all 9 essential amino acids at one sitting, simply eat a varied plant-based diet throughout the day and your body can take care of the rest. One easy way is to combinerice and beans,but you can also just make sure to get a variety ofplant-based foodsand be sure to include legumes like chickpeas in your lunch salad. You don't have to eat all the building blocks at once, as nutritionists once thought since your body has the extraordinary ability to assemble them into the necessary proteins to operate at peak performance.

Eating to support a healthy immune system is as simple as following the basic principles of healthy eating. Your best bet: Consume a variety of foods and try to fill half your plate with fruits and vegetables, and make at least half of the grains you eat whole grains. Try to limit processed foods, excess sodium, added sugars, and saturated fats which drive up inflammation. In addition to proper nutrition and hydration, getting adequate sleep, minimizing and managing stress, and incorporating regular physical activity are all healthy lifestyle choices that help support a healthy immune system.

Go here to see the original:
Eat Protein to Boost Your Immune System. Here's How Much You Need - The Beet

Read More...

Hard-to-treat pancreatic cancer hijacks immune system and could be targeted with immunotherapies – PharmiWeb.com

Wednesday, September 2nd, 2020

Scientists have used artificial intelligence to reveal an aggressive form of pancreatic cancer that is more likely to respond to immunotherapy, in the most extensive analysis of the immune landscape of these tumours to date.

Pancreatic neuroendocrine cancer starts in cells that produce hormones such as insulin. Once it spreads, only one in four people will survive for more than five years, and new treatment options are desperately needed.

The new study found that a particularly aggressive type of these tumours can evade immune attack by hijacking the immune systems response to viral infections, and reveals possible targets for immunotherapy for this rare, hard-to-treat form of pancreatic cancer.

Next, the researchers plan to translate their findings into new clinical trials to test the possible benefit of immunotherapies in those patients most likely to respond.

Scientists at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, working with colleagues at the University and Hospital Trust of Verona, Italy, used AI and genetic analysis to study 207 tumour samples from patients with pancreatic neuroendocrine tumours for the levels of 600 immune-related genes.

Comparing four separate forms of the disease, they found that samples of the most aggressive form, known as metastases-like primary tumours, saw changes in activity of 74 immune-related genes, compared with changes in only 12 immune system genes in the more benign insulinoma-like tumours.

The study was published in the journal Gut today (Tuesday), and was funded by the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (ICR), the ICR itself, and by Italian charities including the AIRC Foundation for Cancer Research.

The scientists found that 83 per cent of aggressive, metastatic-like tumours contained particularly high levels of a gene called TLR3, part of a damage-alert system that mimics the infection response triggered by viruses, drawing immune cells to the tumour.

This damage response is related to a form of programmed cell death that occurs when theres not enough oxygen which can happen inside metastatic-like tumours, which tend to be larger in size.

The researchers believe that by hijacking the damage response through TLR3 which helps flag tumour cells to the immune system cancer cells can escape from the immune system, leading to the tumours ability to grow and evolve.

The ICR, a charity and research institute, is raising the final 2 million for its revolutionary new Centre for Cancer Drug Discovery, dedicated to overcoming cancers ability to evolve resistance to treatment.

Importantly, the ICR team also studied the presence of known targets for existing immunotherapies in all four kinds of pancreatic neuroendocrine tumours.

They found that the most aggressive type had the highest levels of an immune marker known as PD-L1, which suggests they can be targeted with immunotherapies designed to take the brakes off the immune system so it can attack tumour cells, known as checkpoint inhibitors.

Immunotherapy treatments have been shown to work very well in some tumour types but they dont work for everyone and have only shown modest benefits in this form of pancreatic cancer, so it is important to be able to identify the patients who are most likely to benefit from immunotherapy.

The researchers now hope their results will lead to clinical trials to test the benefit of immunotherapies, either alone or in combination with other treatments, for patients with the metastatic-like form of pancreatic neuroendocrine tumours.

Dr Anguraj Sadanandam, Team Leader in Systems and Precision Cancer Medicine at The Institute of Cancer Research, London, said:

Our new study offers an important basis from which to start developing new treatment strategies for a rare form of cancer, which starts in the hormone-producing cells of the pancreas.

We found that there is a complex interplay between cancer and immune cells in the most aggressive type of pancreatic neuroendocrine tumours, which suggests immunotherapy could work for patients with this form of the disease.

Our findings could help to pick out those patients most likely to benefit from immunotherapy and were keen to translate our work into clinical trials to test the benefit of different immunotherapeutic strategies to tackle this hard-to-treat form of pancreatic cancer.

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

Pancreatic cancers have some of the poorest survival rates so its hugely encouraging to see such an extensive study of the immune landscape of a rare form of pancreatic cancer, looking at the underlying biology to inform the best way forward in treating the disease.

Its fascinating to see a mechanism unveiled by which these tumours develop the activity of a highly distinct set of immune-related genes, as this could not only underlie the immune escape of these tumours, but also feed into their ability to evolve one of the biggest challenges in cancer research and treatment today.

Immunotherapy has transformed the outlook for a range of different cancer types, and I look forward to seeing these new findings progress to clinical trials, which might lead to a more personalised way of treating people with pancreatic neuroendocrine tumours.

Read the original:
Hard-to-treat pancreatic cancer hijacks immune system and could be targeted with immunotherapies - PharmiWeb.com

Read More...

FALL 2020 – Magnetude Jewelry Fashion Line Supports the Immune System – PR Web

Wednesday, September 2nd, 2020

Magnetude Jewelry Fall 2020

MT AIRY, Md. (PRWEB) September 01, 2020

In a fall like no other, Magnetude Jewelry finds itself with the right product at the right time. Interchangeable fashion jewelry pendants and necklaces that allow one to change the stone based on mood and occasion is already a hot fashion trend, but in a year where everybody is looking for strategies to boost and improve the immune system, Magnetudes second key ingredient is about what the products are made of: Neodymium magnets.

Most people dont realize that their electrical energy is diminished by EMFs and can decrease their immunity, explains Magnetude co-founder Dr. Tracey Diner, DC. Wearing Magnetude Jewelry along with other healthy regiments like vitamins, good diet, and exercise, help us build up a stronger resistance to viruses and germs.

EMFs come from many sources in this high-tech age, including cell phones, Wifi, cell towers, and other electronic activity. Dr. Diner, a wellness doctor, and her partner Candice Loren, a noted artist and jewelry designer, started this company to pursue their joint passions for unique design and better health.

Magnetude Jewelry incorporates the most powerful healthy Neodymium magnets, energy elements of infrared, negative ion, and germanium in all of their interchangeable necklaces, bracelets, and earrings. These energy frequencies help to replenish the cellular function that EMFs destroy. With the fall flu season about to start and the expected second wave of COVID-19 on the horizon, innovative ways to stay healthier are at a premium.

Magnetude Jewelry should be worn all the time, so it has been designed with thousands of combinations to match any clothing the wearer chooses. There are product lines for men and pets, and this month Dr. Diner says she is launching a childrens line because children are at higher risk from EMFs, absorbing up to 10 times that of adults.

For further information about Magnetude Jewelry and the science behind it, visit http://www.MagnetudeJewelry.com.

Share article on social media or email:

Excerpt from:
FALL 2020 - Magnetude Jewelry Fashion Line Supports the Immune System - PR Web

Read More...

Listen: Plasma and Immunity – The Atlantic

Wednesday, September 2nd, 2020

Wells: Is there any downside of giving people plasma, even if you dont know if its going to be specifically helpful to them?

Hamblin: There theoretically shouldnt be, but there could, and that is the reason that you dont just authorize these things, that you have an FDA to make sure that something is safe and effective ...

Kola: It seems like people have antibodies within three months of them having COVID-19. And I definitely had antibodies back in May when I was given an antibody test, but then, given the news out of Hong Kong, it looks like those antibodies might wane over time? When I imagine the plasma, am I imagining blood that has actual antibodies in it, or does it have the memory of how to make antibodies? Whats actually in the plasma?

Hamblin: Thats a great question Youre just getting the antibodies themselves. The act of producing them will involve the white blood cells that should be taken out of plasma

Wells: Theyre the things that make the antibodies ... and that do have the memory of how to make them?

Hamblin: Right When you transmit plasma, youre not teaching someone to make antibodies. Thats what happens by exposing them to the virus. Thats vaccination. Its called passive immunization, where you temporarily have these antibodies until your blood clears them out. Theyre gone, and youd theoretically have to get another transfusion.

Kola: So there would be the possibility that, having had COVID-19 in March, and maybe being called upon to donate plasma in October, my blood might not have the antibodies anymore that it had in May.

Hamblin: Yeah, that remains possible.

Kola: Wow.

Wells: Is that upsetting?

Kola: I think its like much to do with COVID: Just one of the sort of confusing complexities of it is that I know that I had the antibodies at one point. I cant know for sure that I have them now without another antibody test. And being someone who had it relatively early, my experience of the virus is myself and everyone around me learning about it almost in real time ...

Hamblin: Well, if it helps reassureI guess Katherine can explain the immunology here, because we had a whole episode on thisbut there is more to your bodys memory than just the presence of antibodies themselves. There are immune-messaging pathways such that even if you lost your antibodies, its possible that your body might be able to kind of quickly make new ones and call them back and have other ways of fighting off this virus so that, if you are reinfected, it is not so bad, even if you dont actively have the antibodies.

Kola: Can you explain how people like me who had COVID-19 and are hopeful about immunity should interpret the information from Hong Kong, because that was obviously, on the face of it, quite scary for people whove had an experience of COVID that they wouldnt wish to go through again.

Here is the original post:
Listen: Plasma and Immunity - The Atlantic

Read More...

New COVID-19 Test Shows Patients with Suppressed Immune Systems Can Also Achieve Good Immune Response to SARS-CoV-2 – HospiMedica

Wednesday, September 2nd, 2020

A new test that provides information on the immune response to the novel coronavirus in patients who need to take immunosuppressive drugs has shown that these patients can achieve a good immune response to SARS-CoV-2 despite immunosuppression.

A research team from the University Hospital at Ruhr-Universitt Bochum (RUB Bochum, Germany) has developed the test which can be used to adapt immunosuppressive therapy individually during a COVID-19 infection, such as following an organ transplantation. The test is of great clinical relevance for transplant patients as it provides information that goes far beyond a pure antibody test.

Transplant patients are affected in several ways: in addition to the chronic illness that led to organ failure and subsequent transplantation, transplant patients need to take medications that suppress the defenses of their own immune system. Chronically ill patients with impaired immune defenses have an increased risk of suffering from a severe COVID-19 infection. It was previously unknown whether patients could develop a sufficient reaction against the new coronavirus under the influence of immunosuppressive drugs.

With the help of the test, the team demonstrated that transplant patients are very capable of achieving a good immune response despite immunosuppression. In addition to high antibody titres, large quantities of T lymphocytes, which are responsible for killing infected cells, were found in the current case study.

Until now, it has not been known whether our transplant patients are capable of forming a sufficient immune response to the new coronavirus, said Professor Timm Westhoff, Director of Medical Clinic I at Marien Hospital Herne, who led the team of researchers. The data obtained help us to deal with immunosuppression during the current pandemic. The test allows us to individually adjust immunosuppression when a patient is suffering from COVID-19.

Related Links:Ruhr-Universitt Bochum

Read more from the original source:
New COVID-19 Test Shows Patients with Suppressed Immune Systems Can Also Achieve Good Immune Response to SARS-CoV-2 - HospiMedica

Read More...

29 Fall Superfoods That Will Boost Your Immune System – MSN Money

Wednesday, September 2nd, 2020

How do you strengthen the immune system, the bodys natural defense against disease and infections, is a very common question. The answers often include regular exercise, an adequate amount of sleep, no smoking or excessive alcohol drinking, and of course, a healthy diet.

However, some of these are probably hard to implement during a pandemic. Stress levels are high and most people are simply trying to manage each day as best as they can. Spending a lot of time planning meals that have all food groups is practically impossible, so individual items that have copious amounts of vitamins, minerals, and antioxidants all in one may come in handy.

24/7 Tempo used the U.S. Department of Agriculture site to determine fall foods, and consulted a clinical nutritionist to identify the best fall superfoods that may help boost immunity.

Eating the right foods is not rocket science, and superfoods is not a scientific term. Its a marketing term used to describe foods that are nutritionally dense, although often there are also misconceptions about which fruits and vegetables fit that description. Not all foods are created equal, and you only think some foods are healthy when, in reality, they wreak havoc on your body.

See the rest here:
29 Fall Superfoods That Will Boost Your Immune System - MSN Money

Read More...

COVID-19 & Healthcare: Personalized Medicine is the Future – The National Law Review

Wednesday, September 2nd, 2020

Thursday, August 27, 2020

In this episode, Foley PartnersJudy WaltzandAntoinette Konskitalk withEdward Abrahams, the President of the Personalized Medicine Coalition, to discuss the issues facing personalized medicine and how the concepts underpinning the field may be applied to diagnose and treat COVID-19.

We encourage you to listen to thepodcast in its entirety.

Following is a transcript of this podcast. Please feel free to download aPDF version here.

Please note that theinterview copy below is not verbatim. We do our best to provide you with a summary of what is covered during the show. Thank you for your consideration, and enjoy the show!

Personalized or precision medicine is the field of medicine that finds the best treatment for each patient at the right time. Physicians use diagnostic tests, medical history, circumstances, and values, as well as information from prior patient therapies, to prevent disease and develop targeted therapies that can expedite a patient's treatment and recovery.

The Personalized Medicine Coalition, or PMC, is an advocacy and educational group that represents innovators, scientists, patients, providers, and payers to promote the understanding and adoption of personalized medicine concepts, services, and products. Dr. Edward Abrahams is the president of the PMC and has charted its growth from its original 18 founding members in 2004 to more than 200 members today.

I am pleased to have Ed as our guest to explore issues facing personalized medicine and how its concepts and emerging research may be applied to diagnose and treat COVID-19. Ed, thank you so much for being with us here today. Did I hit the mark on precision medicine? Is there anything you would like to add by way of introduction to yourself or the PMC?

I think you have defined personalized medicine very well indeed. Let me begin by noting, as you just did, that I have never met a patient who did not prefer getting the right medication the first time, rather than going through a process of trial and error because the right diagnosis could not be made in advance of selecting the right therapy.

The good news is that we have many more molecular diagnostics today to target the right treatments to the right patients at the right time, as is often said. But personalized medicine also promises lower costs for systems that incorporate the tests and treatments underpinning the field into their clinical work streams. This is very important. By becoming more efficient with targeted therapeutics and avoiding costly interventions that don't work, personalized medicine can help these systems save money, and, at the same time, provide better outcomes for individual patients.

In other words, and this is terribly important in today's context of constricted resources for health care, with personalized medicine, we can enjoy the benefits of innovation and reduce costs. But we have to be smart about how we develop these opportunities. At present, we have only anecdotal evidence that personalized medicine can deliver both clinical and economic benefits, which is why PMC is doing the research to demonstrate that even if individual therapies come with high price tags, as many in fact do, they can and will produce cost savings if we target them to only those patients who will benefit.

That, in brief, is the real promise of personalized medicine. We believe personalized medicine can provide tremendous value, not only to patients, but also to the systems and countries that in fact have the courage to implement it.

Thank you so much for that explanation and background on personalized medicine and how it is being used today to treat and prevent disease. Ed, for me, one of the highlights of the year is the publication of PMC's annual report that summarizes the key advances the industry has made over the past year. When will the 2020 edition be released, and can you give us a preview of what to expect?

Within the next eight weeks, the Personalized Medicine Coalition will publish the sixth edition ofThe Personalized Medicine Report. We used to call itThe Case for Personalized Medicine, but we now believe that the case has been made.

The report is our effort to define the field by explaining personalized medicine's opportunity, documenting its status, and discussing the challenges it faces. It's a widely read report that is written for laymen, particularly policymakers at federal agencies and on Capitol Hill.

The sixth edition will, for example, show that in 2008, there were only five personalized medicines, which we define as therapeutics with biomarker strategies on their labels, on the market. Today, there are over 250, so you can see there's been enormous progress over these past 10 years or so.

While most of these products are in oncology, we have also seen progress in other indications as well, including cardiovascular illness, depression, and especially rare diseases. The report will also show that today there are 75,000 genetic testing products on the market, up from fewer than 66,000 in 2016. In other words, this is an exploding field.

Also new in this report are discussions of how advanced analytics, artificial intelligence, and machine learning are yielding new insights about how other biological and environmental factors, in addition to genetics, influence a patient's disease risk and response to various treatments, thus opening the door to preventive medicine, one of personalized medicines most important if as yet unrealized promises.

The report documents how, by targeting effective treatments to those patients who benefit, personalized medicine can achieve key goals for patients and health systems. It can shift the emphasis in medicine from reaction to prevention with emerging technologies like liquid biopsies, which may be able to detect cancer before any symptoms occur. This is tremendously important and a great promise. It may reduce trial-and-error prescribing, which patients would absolutely love.

Personalized medicine can also cut the number of adverse drug reactions, which right now are the third or fourth largest cause of death in the United States. It can use cell-based or gene therapy to replace or circumvent molecular pathways associated with disease, thereby offering cures where none had existed before. It can reveal additional targeted uses for medicines and drug candidates. It will obviously increase patient adherence to treatment, as patients will be more likely to stay on medications that don't have dangerous side effects, for example.

Personalized medicine will also reduce high-risk invasive procedures, which it already has done in say, kidney transplants, for example. It will help move patient-physician engagement toward patient-centered care. And finally, as I mentioned, it could and should reduce the overall cost of health care.

The report makes the argument that outstanding challenges in regulation, reimbursement, and clinical adoption slow our efforts to capitalize on advances made possible by personalizing treatments. Overcoming these obstacles, as we write, will require a collaborative effort to keep up with the pace of progress in science and technology. And this is in fact the overall mission of the Personalized Medicine Coalition.

At the end of the dayand you mentioned this a bit in your commentsfor personalized medicine to be a success and available to patients, it has to be adopted by the clinicians. How does that happen, and are there obstacles to that success?

This is a key thrust of the Personalized Medicine Coalition because we are learning that clinical adoption is a much slower process than patients want and expect. For example, PMC will publish a study this week documenting that medically appropriate genomic testing is quite inconsistent across the United States.

That means, for example, that some patients in cancer are not getting available treatments they need. The study shows that coverage and reimbursement strategies are not the only barriers to personalized medicine, as you might expect. Other barriers include lack of awareness among providers and patients, not to mention socioeconomic factors, including distance and access issues.

In medicine, it doesn't necessarily follow that if you build it, they will come. There are many mediators along the way from discovery and development to adoption. We also know from another PMC-commissioned study of the value of genomic testing in cancer care, for example, that many patients who are eligible for effective targeted therapies, as determined by genomic sequencing of their tumor, still do not receive the best treatment option based on the results.

This practice gap can be attributed to the limitations in the availability and interpretation of test results, sample processing constraints, limited access to targeted therapies, and especially lagging awareness of the rapidly evolving field of personalized medicine among physicians and other providers.

We demonstrate in this study that if all patients who were eligible to receive a targeted treatment actually received it, the cost-effectiveness of genomic sequencing, which is sometimes alleged to be too high, would significantly improve. In short, along with public policy, we know that the downstream issues focused on clinical adoption are extremely important and must be addressed.

We are in a continuing debate with respect to drug pricing in the United States. How does that debate impact the future of personalized medicine and how would you address or make some recommendations as to how we price our drugs?

That's a very important question because as you know, the drug pricing debate has gripped public attention. But we are not considering all ramifications. The debate has particular implications for the development of personalized medicines, which tend to be more expensive but may together have a positive impact on the health care system and on overall costs.

We have to ensure that innovative products remain accessible, including to those who cannot afford them. But we also have to be careful not to remove the incentives to discover and develop those products in the first place, which I am afraid that price controlsno matter how they are implementedwould do. That is to say, they would stifle innovation. Drug development is a risky business. There are no guarantees. If we move or decrease the financial incentive to find new cures to unmet medical needs, it follows that we're going to see fewer interventions.

Late last month, President Trump issued an executive order to tie the prices paid for physician-administered drugs, many of which are personalized medicines, to those that are paid in other countries. That may be politically popular because those other countries pay less. But the policy, if implemented, will have disastrous unintended consequences for the development of say, new cell-based therapies, gene therapies, and targeted medicines that are only now reshaping health care in ways no one thought possible ten years ago.

This is so because there are incentives in place to encourage the development of groundbreaking therapies. It's important to understand that when a pharmaceutical company invests in, say, finding a one-shot cure for spinal muscular atrophya rare and debilitating disorder that affects fewer than 25,000 people in the United Statesit does so without any guarantee of success, and it does so also with very high up-front costs that must be recovered. If the company that develops the cure cannot get a return on its investment, it's unlikely to take these big risks upon which patients depend. Long story short, patients will suffer and the costs of providing carenot curesfor those patients will remain higher than they could be.

I'd like your opinion on a topic of current urgent and global concern. Today, we are challenged medically and economically with the COVID-19 pandemic. How have the principles of personalized medicine been applied to diagnosing and treating COVID-19?

I actually believe that the principles of personalized medicine that emphasize stratified responses, even when it comes to public health, have significant implications for diagnosing and treating COVID-19. Those principles, I believe, should inform future interventions to stem this terrible pandemic that has already killed over 170,000 people in the United States alone.

I don't think these principles are being adequately considered as part of the debate. PMC looks forward to introducing those principles, because they're so very important if we're going to effectively address this pandemic.

First, we have been very slow to develop and deploy real-time diagnosticsthe backbone of personalized medicine. These diagnostics give us the tools to determine who is at risk, so we don't have to put in place one-size-fits-all public health responses, including closing down whole economies, when that might not be necessary if we knew who had the disease or who was likely to get the disease.

To date, we have not been able to target long-term prevention and treatment plans to the most at-risk populations, which would be enormously helpful in reopening economies, which we would obviously like to do sooner than later.

Second, and equally important, we know that the coronavirus expresses itself differently among different populations. For example, older men, racial and ethnic minorities, and those with particular underlying conditions seem to be more vulnerable to disease. It behooves us, therefore, to understand the molecular and environmental reasons for this differentiated response, and to develop and deploy therapies and vaccines that are targeted to those who are in need.

Today, we are looking for one-size-fits-all solutions because there's an urgency to find one. But eventually, scientists in my opinion are going to recognize that, because not everyone responds the same, different medicines are going to have to be developed to treat COVID-19 and other viruses.

We've already seen this in AIDS, and so I don't think the coronavirus is going to be different. We have to be really smart about how we address this pandemic. By the way, on September 3rd, PMC is organizing a virtual seminar, titledCOVID-19 and Personalized Medicine: Current Status and Lessons Learned. It is free, and if you want to register, you can do so on ourwebsite.

Ed, thank you so much for being with us today, and as we wrap up, I'd like to invite you to make any closing remarks or comments on the topics we covered today.

I'd really like to thank you both for your loyal support to the Personalized Medicine Coalition, and for giving me the opportunity to discuss these very important issues with your audience. I hope people will pay attention to personalized medicine. We believe it represents the future, and we also believe that if we invest in it, if we come together collaboratively as a community, we can have a health care system that we deserve based upon the developments in science and technology, which have never been more promising. Again, thank you for your attention, and I look forward to working with you and everybody on this podcast to move this field forward. It's not going to happen by itself.

Here is the original post:
COVID-19 & Healthcare: Personalized Medicine is the Future - The National Law Review

Read More...

Is 43 Too Young for Colon Cancer? UC San Diego Health Experts Available to Talk About Colorectal Cancer – Newswise

Wednesday, September 2nd, 2020

With the recent death of actor Chadwick Boseman, many may be wondering how a seemingly healthy adult is diagnosed with a disease often thought of as illness of older adults. Although colorectal cancer is most often diagnosed in people 50 years or older and incidence rates in this age group are, in fact, declining, the number of adults under 50 diagnosed with colorectal cancer is rising. According to the National Cancer Institute, approximately 5 percent of all new cases of colorectal cancer in the United States are among persons 15 to 39 years old.

African Americansbear a disproportionate burden of cancer. Studies have shown that those who are diagnosed with colorectal cancer at a young age have worse survival outcomes compared to young white patients.

With improvements in prevention, early detection and treatment, there are more than 1.5 million colorectal cancer survivors living in the U.S. Still, an estimated 53,200 people will die this year, making this disease the third most deadly cancer among men and women in the U.S. Approximately 147,950 people will be diagnosed in 2020. Thats one in 23 men and one in 25 women who will develop colon or rectal cancer, the two malignancies that make up colorectal cancer.

At UC San Diego Health, a comprehensive team of medical, surgical and radiation oncologists use the most advanced treatment options, such as laparoscopic surgery and personalized medicine. At Moores Cancer Center, patients can enroll in clinical trials specifically for colorectal cancer.

Oncologists with Moores Cancer Center are available to answer questions about this disease.

###

Follow this link:
Is 43 Too Young for Colon Cancer? UC San Diego Health Experts Available to Talk About Colorectal Cancer - Newswise

Read More...

Biocompatible TeSex nano-alloys for PT/PA/CT/PET imaging-guided NIR-II-photothermal therapy – Science Codex

Wednesday, September 2nd, 2020

Nanotheranostics, integrating diagnostic and therapeutic functions by nanoplatform, exhibits a great potential in precision and personalized medicine, and also raises the requirement on multifunctional nanomaterials in pursuit of both good biocompatibility and high theranostic performances. The emergence of diverse multifunctional nanomaterials and advanced nanotechnologies unprecedentedly simulates the evolution of nanotheranostics, and enables the integration of multimodal imaging and therapeutic functions in a single theranostic nanoparticle for high-efficacy theranostics of diseases. In engineering of theranostic nanoplatforms, biocompatibility and multifunction are two most important factors which need to be considered. Among various nanotheranostics, multimodal imaging-guided photothermal therapy has attracted intensive attention owing to its less invasiveness and lower side effects compared with conventional radiotherapy and chemotherapy.

In a new article published in the Beijing-based National Science Review, scientists in Shenzhen University, China, hypothesize that controllable incorporation of biocompatible Se element into the lattice of Te nanostructures for construction of TeSex nano-alloys could intrinsically tune the inherent cytotoxicity of Te nanomaterials, enhance the biocompatibility of Te nanomaterials and extend their functions for biomedical applications. In this work, a series of TeSex nano-alloys with different Se incorporating proportions are synthesized to investigate their biocompatibility and develop their theranostic functions. It is determined that the toxicity of Te nanomaterials mainly comes from irreversible oxidation stress and intracellular imbalance of organization and energy, which is exterminated by the nano-alloying by incorporating a moderate proportion of Se (x=0.43). The synthesized TeSex nano-alloy exhibits extraordinarily high NIR-II-photothermal conversion efficiency (77.2%), 64Cu coordination and CT contrast capabilities, enabling high-efficacy photothermal therapy of cancer under the guidance of multimodal PT/PA/PET/CT imaging.

Several main advances are achieved. (1) Advanced TeSex nano-alloys are facilely constructed to intrinsically eliminate the inherent toxicity of Te nanomaterials by the moderate incorporation of biocompatible Se. (2) Advanced mechanisms for Te nanomaterial toxification and TeSex alloying detoxification are uncovered. (3) Advanced theranostic performances with ordinarily high NIR-II-photothermal efficiency and multimodal PT/PA/CT/PET imaging capability are achieved by proposed nano-alloying strategy.

See the article here:
Biocompatible TeSex nano-alloys for PT/PA/CT/PET imaging-guided NIR-II-photothermal therapy - Science Codex

Read More...

Men’s Health Expert Tracy Gapin, MD Unveils Male 2.0 with a Revolutionary Protocol to Conquer the Men’s Health Epidemic – PRNewswire

Wednesday, September 2nd, 2020

SARASOTA, Fla., Sept. 1, 2020 /PRNewswire/ --Transcendent Publishing today announced the release of Male 2.0: Cracking the Code to Limitless Health and Vitality by author Tracy Gapin, MD, FACS. Since its August release, the book has already reached Amazon bestseller status. Dr. Gapin, a men's health and performance expert and member of the American Urological Association, provides a meaningful impact for men's health with this leading-edge approach.

Over the past thirty years, there has been a relentless population-based decline in mens' testosterone levels by over thirty percent. We've also seen a dramatic increase in the incidence of obesity. Over seventy percent of men are either overweight or obese, which is directly tied to energy, productivity, and overall health and performance. This has led to a men's health epidemic for the 159 million men in the United States.

The Male Method described throughout Male 2.0 was developed to help men lose weight, regain energy, optimize their hormones, and regain peak performance. "We need to go beyond testosterone. We need to take an individualized, systems-based approach to optimize men's health, performance and longevity," says Tracy Gapin, MD, FACS. "Driven by the power of epigenetics, genetics, peptides, and wearable technologies, we have gained incredible insight into some of the most misunderstood aspects of men's health and longevity."

JJ Virgin, New York Times Bestselling author of The Virgin Diet & Sugar Impact Diet said, "As a thought leader in men's health, Dr. Gapin has provided the modern-day blueprint to help men optimize their health and regain their vitality. Every man should read this book."

Clete Walker, CEO of Vituro Health, a prostate health company, said, "Male 2.0 is a revolution for men's health. After my father was diagnosed with prostate cancer, I made it my mission to seek out potential new modalities, and this data-driven approach is the future."

Male 2.0: Cracking the Code to Limitless Health and Vitalityis available on Amazon and during the month of September the print version is available for free at The Gapin Institute. http://www.GapinInstitute.com

About Tracy Gapin, MD FACS:Dr. Gapin is board-certified Urologist, world renowned Men's Health & Performance Expert, Author, and Professional Speaker. Using state-of-the-art biometric monitoring, nutrition and lifestyle intervention, Dr. Gapin coaches Fortune 500 executives and evolutionary leaders of business, sports medicine, and high performance. He specializes in cutting-edge precision medicine with an emphasis on epigenetics, providing men with a personalized path to optimizing health & performance. http://www.GapinInstitute.comEmail: [emailprotected]

About Transcendent Publishing:Since 2012, Transcendent Publishing has specialized in offering a variety of publishing and design services for today's indie author. http://www.transcendentpublishing.com

CONTACT:Leann Spofford[emailprotected]Tel: (941) 524-4592

SOURCE Gapin Institute

Home – MMG

See the article here:
Men's Health Expert Tracy Gapin, MD Unveils Male 2.0 with a Revolutionary Protocol to Conquer the Men's Health Epidemic - PRNewswire

Read More...

Postdoctoral Researcher in Biological Network Modelling job with UNIVERSITY OF HELSINKI | 223494 – Times Higher Education (THE)

Wednesday, September 2nd, 2020

A postdoctoral position is available at the Faculty of Medicine, University of Helsinki, Finland to work in the research group of Dr. Jing Tang (https://www.helsinki.fi/en/researchgroups/network-pharmacology-for-preci...). The position is part of an Academy of Finlands research project that aims to do network pharmacology modeling to provide the mechanism of action of drugs and drug combinations for a systems-level understanding of cancer. The Tang group combines computational methods to offer improved efficiency methods to identify more effective cancer treatments for personalized medicine. The Tang laboratory is based at Research Program in Systems Oncology (ONCOSYS) (https://www.helsinki.fi/en/researchgroups/research-program-in-systems-on...) at the Meilahti biomedical campus.

Role description:

We are seeking at least one postdoctoral researcher to work on the computational methods to develop network pharmacology models for predicting drug combinations. The project is focused on strategies for predicting potential drug combination and patient subclasses by constructing multipartite networks using drug response data. The primary goal of the project is to analyse drug sensitivity datasets to exploit drug-target interaction data to explore the biological mechanism of drugs. A key aim of the work is to propose drug combination regimens focusing on patient-derived drug response data along with the providing a biochemical and biophysical understanding of a drug combination. Hematological malignances and ovarian cancer are the available datasets for this project. The post holder will be responsible for planning and conducting computational research within the project under the supervision of Dr. Mohieddin Jafari, and Prof. Jing Tang.

The ability to work well within a collaborative team is critical for this position. You will work with unique datasets derived from large-scale experiments associated with a diverse range of projects in pharmacology and molecular biology. Salary will be commensurate with qualifications and experience based on the University guidelines. The full-time position start Jan 2021. A six-month trial period will be applied.

Key requirements:

We are seeking a creative and highly motivated individual with primary interest in network science and biomedical data mining. Candidates should have a PhD in bioinformatics, computational biology, statistics, computer science or other related disciplines. The ideal candidate will have experience in at least one of the aforementioned areas, and a strong interest in the others. Previous experience with biological networks, omics datasets, and expertise in related statistics and modelling are considered an advantage. Solid skills in scripting/programming (preferably R and Python) are essential prerequisites for this position. Excellent communication and presentation skills in English, good organisational skills, troubleshooting expertise and the ability to work effectively to tight deadlines are desirable.

Appointment details:

The position is available from October 2020 onwards, and can be started later upon agreement. It is a two-year fixed-term position, with a possibility of extension. Trial period of 6 months will be applied. The salary will be based on level 5 of the demands level chart for teaching and research personnel in the salary system of Finnish universities. In addition, the appointee will be paid a salary component based on personal performance with the overall starting salary amounting to approximately 3300-3600 EUR per month, depending on the qualifications and previous relevant research experience of the candidate.

Application details:

Please submit your application via the University of Helsinki Recruitment System by clicking the Apply for the position button below. Internal applicants (i.e. current employees of the University of Helsinki) should submit their applications through the SAP HR portal. If you need support with the recruitment system, please contact recruitment@helsinki.fi.

Please attach the following documents to your application as a single PDF file:

The deadline for applications is September 30th 2020. Interviews will be conducted either in person or online. For more information on the position, please contact Dr. Mohieddin Jafari (mohieddin.jafari(at)helsinki.fi) and Prof. Jing Tang (jing.tang(at)helsinki.fi).

The University of Helsinki (UH), founded in 1640, is a vibrant scientific community of 40,000 students and researchers. It is one of the leading multidisciplinary research universities and ranks among the top 100 international universities in the world. It is currently investing heavily in life sciences research. UH offers comprehensive services to its employees, including occupational health care and health insurance, sports facilities, and opportunities for professional development.

Together with the Helsinki University Hospital (HUS) and the Helsinki Institute of Life Sciences (HiLIFE), the Faculty of Medicine, University of Helsinki, constitutes the Academic Medical Center Helsinki (AMCH). This medical center has been very successful in international comparisons, ranking among the top 10 medical campuses in Europe and among the top 50 globally.

Research Program in Systems Oncology (ONCOSYS) consists of basic, translational and clinical researchers who use cutting-edge measurement technology, patient data and AI methods in cancer research and oncology. The overall objective of ONCOSYS is to understand the underlying causes of cancer progression or treatment resistance, and to develop effective diagnostic, prognostic and therapeutic approaches.

Due date

30.09.2020 23:59 EEST

Read the original:
Postdoctoral Researcher in Biological Network Modelling job with UNIVERSITY OF HELSINKI | 223494 - Times Higher Education (THE)

Read More...

Medical Practice Income, Inc., a Subsidiary of USA Equities Corp. (USAQ), Announces the Early Success of QHSLab Launch in South Florida -…

Wednesday, September 2nd, 2020

West Palm Beach, FL, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Medical Practice Income (MPI), a subsidiary of USA Equities Corp. (OTC Link: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, is proud to announce the early success of the QHSLab launch in South Florida. Since launching the platform on June 30, 2020, 159 medical practices have provided 374 allergy patients with a QHSLab-generated allergen immunotherapy prescription, generating an estimated $664,608 in reimbursement revenue to these physicians practices.

There are over 450,000 primary care physicians, including licensed nurse practitioners, in the United States. Many are reporting higher rates of fatigue and burnout due to long hours, heavy patient caseloads, and declining practice revenue from a lack of healthcare reimbursements. Primary care physicians are particularly overwhelmed by the number of patients suffering from allergies, which often signal other health related and immune compromising concerns. Doctors need smart, digital medicine solutions that save time and money, while delivering the right treatment to patients that need it. With the addition of QHSLab, not only will physicians be better equipped to treat patients, but they will also be able to sustain their practices with ongoing revenue through healthcare reimbursements, generating new income per practice, per year.

Allergies alone are estimated to affect 1 in every 5 Americans and costs upwards of $18 billion in direct health and medical expenditures annually. It not only impairs quality of life, but is responsible for as much as $4 billion annually in lost productivity due to work and school absences. When over-the-counter allergy medication treatment is no longer successful, allergen immunotherapy is recommended. Allergen immunotherapy is usually prepared by allergy specialists however, today there is a published shortage of board-certified allergy specialists available to treat the number of allergy sufferers.1 Patients must now rely on their primary care provider to effectively manage their allergies. Through our AI-enhanced, physician-directed platform, MPIs QHSLab, were increasing the primary care physicians ability to effectively address their patients chronic conditions, while saving them time and potentially expensive visits to a specialist when not absolutely necessary, said Troy Grogan, President and CEO of Medical Practice Income, Inc and USA Equities Corp.

The Fall of 2020 is soon upon us, but this season will be even more alarming than usual due to the ongoing spread and impact of COVID-19. Fredric Pullen MD, FACS, an Allergy and Ear, Nose & Throat Specialist based in Palm Beach Gardens, FL shared the following insight regarding QHSLab: Its so much easier for busy primary care physicians to have a software system that can automatically generate the patients allergy formulas for their appropriate immunotherapy, based on their allergy test results. It saves time and potential error which is a definite plus for non-allergy specialist doctors, especially in the age of COVID-19.

For more information about Medical Practice Income, or to become a participating physician, please visit https://www.medicalpracticeincome.com/opportunities.

About USA Equities Corp (OTC Link: USAQ)

On December 20, 2019 USA Equities Corp entered into and consummated a share exchange with the former stockholders of Medical Practice Income, Inc. (MPI), a Florida corporation. As a result of the Share Exchange, MPI became our wholly-owned-subsidiary. We are focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Companys intellectual properties, products and information service portfolio is directed towards prevention, early detection, management and reversal of cardio-metabolic and other chronic diseases. Our principle objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population and is located in West Palm Beach, Florida. For more information, visit http://www.MedicalPracticeIncome.com/discover.

Forward-Looking Statements

This press release contains forward-looking statements which are identified by words such as may, could, believes, estimates, targets, expects, or intends and other similar words that involve risks and uncertainties. These statements have not been based solely on historical facts but on USA Equities Corp current expectations about future events and results. You should consider that as such statements relate to future matters, they are subject to various inherent risks, uncertainties and assumptions that could cause actual results or events to differ materially from expectations described in the forward-looking statement. Various important factors could cause actual results or events to differ materially from the forward-looking statements that USA Equities Corp makes, including, but not limited to, the risk that software development and studies may be delayed and may not have satisfactory outcomes, the risk that costs required to continue our Software as a Service (SaaS) or to expand our operations will be higher than anticipated and other risks described in the Risk Factors section of our Annual Report on Form 10-K filed by USA Equities Corp with the SEC on February 21, 2020. Except where required by law, USA Equities Corp. has no intention to update or revise forward looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation. None of USA Equities Corp Directors, Consultants, or any other person named with their consent in this presentation can assure you that any forward-looking statement or result expressed or implied by any forward-looking statement will be achieved.

Read more from the original source:
Medical Practice Income, Inc., a Subsidiary of USA Equities Corp. (USAQ), Announces the Early Success of QHSLab Launch in South Florida -...

Read More...

Page 43«..1020..41424344


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick